Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study.

Roberto De IccoGiuseppe FiamingoRosaria GrecoSara BottiroliChiara DemartiniAnna Maria ZanaboniMarta AllenaElena GuaschinoDaniele MartinelliAlessia PutortìValentina GrilloGrazia SancesCristina Tassorelli

Published in: Cephalalgia : an international journal of headache (2020)

Different migraine phenotypes, characterized by different treatment susceptibility, may exist as suggested by the divergent behavior between neurophysiological and biomolecular findings in 30% Responder vs. NON-responder patients.The study protocol was registered at clinicaltrials.gov (NCT04361721).

Keyphrases

end stage renal disease
study protocol
newly diagnosed
randomized controlled trial
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
double blind
placebo controlled